Jun 16, 2026

AmMax Bio Names Biopharmaceutical Executive Travis Read as President and Chief Operating Officer

Read More Jun 9, 2026

AmMax Bio Licenses Antibody-Drug Conjugate Technology for Hematological Cancers from Lonza

New agreement provides AmMax with access to Lonza’s GlycoConnect®, HydraSpace®, and SYNtecan™ linker-payload technologies Agreement to target development of novel antibody-drug conjugates (ADCs) for oncology indications Read More Mar 18, 2025

AmMax Bio Presentation at BIO-Europe Spring 2025

Tuesday, March 18th @ 9:45 AM CET Read More Mar 11, 2025

AmMax Bio Announces Presentation at BIO-Europe Spring 2025

Read More Jan 27, 2025

AmMax Bio Announces First Patient Dosed in Phase 2a Study Evaluating AMB-066 in Patients with Colorectal Cancer Minimal Residual Disease

AMB-066 is a potential first-in-class treatment for CRC MRD ~20,000 patients diagnosed annually in U.S.; no currently approved therapies Read More Dec 10, 2024

AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

Collaboration to evaluate monoclonal antibody as first-in-class treatment in this setting Read More Sep 27, 2024

AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase

Oncology pipeline led by first-in-class treatment for patients suffering from colorectal cancer with minimal residual disease (CRC MRD) Read More